Drug Research, Table of Contents Drug Res (Stuttg) 2014; 64(S 01): S11-S12DOI: 10.1055/s-0033-1358031 Symposium der Paul-Martini-Stiftung Georg Thieme Verlag KG Stuttgart · New YorkAntibiotische Therapie der Pneumonie – Was gibt es bei CAP, HAP und VAP zu bedenken? Authors Author Affiliations T. Welte Direktor der Klinik für Pneumologie, Medizinische Fachhochschule Hannover Recommend Article Abstract Full Text References Literatur 1 Höffken G, Lorenz J, Kern W et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie 2009; 63: e1-e68 2 Dalhoff K, Abele-Horn M, Andreas S et al. Epidemiology, diagnosis and treatment of adult patients with nosocomial pneumonia. S-3 Guideline of the German Society for Anaesthesiology and Intensive Care Medicine, the German Society for Infectious Diseases, the German Society for Hygiene and Microbiology, the German Respiratory Society and the Paul-Ehrlich-Society for Chemotherapy. Pneumologie 2012; 66: 707-765 3 Dalhoff K, Ewig S. Guideline Development Group. Adult patients with nosocomial pneumonia: epidemiology, diagnosis, and treatment. Dtsch Arztebl Int 2013; 110: 634-640 4 Awad SS, Rodriguez AH, Chuang YC et al. A Phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis 2014; Apr 9 [Epub ahead of print]
